NewAmsterdam Pharma (Nasdaq: NAMS) said CFO Ian Somaiya and EVP Matthew Philippe will present in a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 11:45 a.m. ET. A live webcast and archived replay will be available via the company investor relations site.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – NAMSW
-5.10%
-5.10%Session close to close
In the Apr 8 session, NAMSW declined 5.10%, reflecting a notable negative market reaction.
The stock moved -5.1% in the session following this news. A negative reaction to this conference ann...
Analysis
The stock moved -5.1% in the session following this news. A negative reaction to this conference announcement could resemble the -15.41% move following the January 2026 strategic update, where operationally positive details did not prevent downside. Past conference-related and corporate news sometimes coincided with gains, but investor focus has shifted at times toward financial metrics like declining $22.5M 2025 revenue and sizeable $203.8M net loss, which can overshadow neutral outreach events.
Key Figures
Conference time:11:45 a.m. ETCash balance:$728.9M2025 revenue:$22.5M+5 more
Highlight of 2025 achievements, EMA decision timing, trials and cash runway.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
News-driven moves have mostly aligned with sentiment, with one notable negative divergence despite seemingly positive operational updates.
Recent Company History
Recent news for NewAmsterdam has included equity inducement grants, a major 2025 earnings and corporate update, and conference participation. The Feb 18, 2026 full-year 2025 report highlighted $728.9M cash, multiple Phase 3 trials, and regulatory progress, and the stock moved +12.04%. A conference presentation on Feb 4, 2026 coincided with a 7.05% move. By contrast, a strategic update on Jan 9, 2026 with cash of about $729M saw a -15.41% reaction. Today’s conference-focused announcement fits the pattern of frequent investor engagement.
"with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies"
A form of cholesterol carried in the blood that tends to deposit fatty material on artery walls, often called “bad” cholesterol; think of LDL as delivery trucks that sometimes drop sticky cargo along the body’s highways. Investors monitor LDL because drugs, medical devices, and diagnostic tests that change LDL levels or how they’re managed can drive healthcare spending, regulatory approvals, and company earnings, affecting valuations and risk in health-related businesses.
ldl-cmedical
"with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies"
LDL-C stands for low-density lipoprotein cholesterol, the portion of cholesterol carried in the blood by LDL particles that is commonly linked to buildup of plaque in arteries—think of it like sticky debris that can clog pipes. Investors care because changes in LDL-C are a key measure used by regulators and clinicians to judge the effectiveness of cardiovascular drugs and devices, shape insurance coverage, and influence market demand for treatments that lower heart attack and stroke risk.
cardiovascular diseasemedical
"medicines for patients at risk of cardiovascular disease (“CVD”) with elevated"
A group of conditions that affect the heart and blood vessels, such as heart attacks, strokes and clogged arteries. Think of the cardiovascular system as a body’s plumbing and engine: when pipes narrow or the pump fails, treatment, devices and long-term care become necessary. Investors watch these diseases because their prevalence drives demand for drugs, devices and services, influences healthcare costs and insurer payouts, and affects workforce productivity and regulatory risk.
NAARDEN, the Netherlands and MIAMI, April 08, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 11:45 a.m. ET.
A live webcast of the fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company’s website.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
When will NewAmsterdam Pharma (NAMS) present at the Needham Virtual Healthcare Conference?
NewAmsterdam Pharma will present on April 13, 2026 at 11:45 a.m. ET. According to NewAmsterdam, CFO Ian Somaiya and EVP Matthew Philippe will participate in a virtual fireside chat and answer investor questions during the scheduled session.
How can investors watch the NewAmsterdam Pharma (NAMS) fireside chat on April 13, 2026?
Investors can watch the live webcast via the company investor relations site at ir.newamsterdampharma.com. According to NewAmsterdam, the webcast starts at 11:45 a.m. ET and an archived replay will be available on the company website after the event.
Who from NewAmsterdam Pharma (NAMS) will speak at the Needham conference presentation?
CFO Ian Somaiya and EVP, Head of Investor Relations Matthew Philippe will speak at the fireside chat. According to NewAmsterdam, both executives will discuss company developments and engage with investors during the virtual session on April 13, 2026.
Will a replay of the NewAmsterdam Pharma (NAMS) Needham presentation be available after April 13, 2026?
Yes. An archived replay will be posted on the company website after the live webcast. According to NewAmsterdam, the replay will remain accessible through the investor relations site for investors who cannot attend the live April 13, 2026 session.
What topics will NewAmsterdam Pharma (NAMS) likely cover in the April 13, 2026 fireside chat?
The company will discuss recent clinical and investor-focused developments relevant to its CVD pipeline. According to NewAmsterdam, the fireside chat led by its CFO and EVP of investor relations will focus on corporate updates and program status for patients with elevated LDL-C.
